VolitionRx webinar: Breakthrough liquid biopsy method for cancer detection

VolitionRx webinar: Breakthrough liquid biopsy method for cancer detection

VolitionRx — 6 videos in collection

More on this equity

VolitionRx (NYSE: VNRX) and Edison recently hosted a webinar, during which the company provided insights into its progress in early cancer detection screening. The presentation included updates from Volition’s Dr Jake Micallef (chief scientific officer), Mr Gael Forterre (chief commercial officer) and Dr Andrew Retter, a leading UK-based haematologist and medical consultant at Volition.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free